ClearNote Health (formerly Bluestar Genomics) – Cancer detection company enabling people at risk for high-mortality cancers to live longer, healthier lives.

They focus on developing non-invasive tests to detect cancer through a standard blood draw earlier than existing methods by harnessing the power of epigenomics. They apply their proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops.

With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases. Headquartered in the U.S, the company’s CLIA and CAP-accredited laboratory is located in San Diego, Calif., with additional presence in the San Francisco Bay Area and internationally.


Biotechnology

Clearnote Health

Dave Mullarkey

Danielle Scelfo

Gulfem D. Guler

Anna Bergamaschi

Eric Nilson

Samuel Levy

Wayne Volkmuth

Jim Vaughn

The Advisory Team at Clearnote Health provides strategic guidance and expertise to support the company's mission of developing non-invasive cancer detection tests. Comprised of experienced professionals and board members, the team advises on research, clinical development, regulatory pathways, and market strategy to accelerate the commercialization of early detection tests for high-mortality cancers.

Advisory Team

Scientists Team

Clinical Research Team

Advisory Team

About

Team members

Other teams at Clearnote Health

Scientists Team

Clinical Research Team